1. Introduction {#sec1}
===============

Cardiovascular diseases represent the leading cause of death worldwide and may result from the association of different cardiometabolic risk factors \[[@B1]\]. When such factors simultaneously cluster in the same individual, they contribute to the establishment of Metabolic Syndrome (MetS), a condition characterized by the combination of increased blood pressure and glycemic levels, dyslipidemia, and abdominal obesity \[[@B2]--[@B4]\], which directly increases the risk of cardiovascular disease in its carriers \[[@B1], [@B2]\]. Indeed, the MetS participates in various pathological metabolic processes, with possible negative outcomes on the general biochemical profile \[[@B5]\], redox balance \[[@B4]--[@B6]\], and arterial function \[[@B1], [@B7]\].

When considering the MetS diagnostic parameters, a huge body of evidence points to their relation with the oxidative stress \[[@B4], [@B5], [@B8]\]. The latter, also known as redox imbalance, is characterized by a condition in which the excess of reactive oxygen and nitrogen species (RONS) compromises or even surpasses the action of endogenous antioxidant systems, either for increase in prooxidants, such as RONS, or for decreased antioxidant defense \[[@B9]\]. The oxidative stress implies pleiotropic toxic effects on cellular metabolism \[[@B4], [@B10]\], with potential damage to different organic systems \[[@B5], [@B11]\], especially in the vasculature \[[@B10], [@B12]\]. Concerning the association between oxidative stress and the MetS, literature reports are not consensual when it comes to the pattern of redox balance in patients presenting with MetS \[[@B6], [@B8], [@B13]\].

Myeloperoxidase (MPO), a heme peroxidase abundantly expressed in leukocytes, is a central enzyme in innate host defense \[[@B14], [@B15]\]. Primarily stored in cytoplasmic granules \[[@B16]\], MPO may be released to the extracellular compartment after phagocyte activation \[[@B17], [@B18]\]. Using hydrogen peroxide (H~2~O~2~) as a cosubstrate, MPO participates in the formation of different oxidants, among which are hypohalous acids \[[@B16]\]. Despite its beneficial effects related to leukocyte-mediated protection against pathogens, its excessive activity may imply tissue damage through oxidant production \[[@B15]\], being involved in chronic inflammatory conditions \[[@B14]\], among which are atherosclerosis and coronary artery disease \[[@B19]\], and also promoting endothelial dysfunction \[[@B20]\]. In this respect, however, even though several lines of evidence point to the association between the parameters related to the MetS and oxidative stress \[[@B12], [@B21], [@B22]\], the in-depth mechanisms involved in the pathophysiology of the MetS, particularly those related to its components, oxidative stress, and arterial function, still remain poorly understood. Based upon this scenario, the present work aims to assess the oxidative stress profile in patients with MetS and their arterial status, and also to evaluate a possible pathway through which oxidative stress markers may contribute to systemic lipid peroxidation.

2. Materials and Methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

For this case-control study, a total of twenty-four patients with MetS and eighteen apparently healthy subjects were nonprobabilistically selected from the ambulatory of Endocrinology at the Teaching Hospital of the Federal University of Alagoas and from the adjacent community, respectively. Patients were paired for age, sex, tobacco use, dietary habits, and socioeconomic status. The steps from selection until the clinical and biochemical assessments are presented in [Figure 1](#fig1){ref-type="fig"}. The study protocol was approved by the Ethical Committee of the Federal University of Alagoas (Protocol number 010501/2009-91) and was in accordance with the principles outlined in the Declaration of Helsinki. All subjects gave written informed consent before carrying out the procedures.

The diagnosis of MetS was made based on the criteria defined by the International Diabetes Federation \[[@B23]\]. For both groups, exclusion criteria were age \<30 or \>65 years, patients taking antioxidant supplements, individuals presenting abnormalities which precluded the arterial assessment using radial artery applanation tonometry (e.g., patients with known arrhythmia, using pacemakers and those in which the left radial artery palpation could not be properly performed), pregnant or lactating women, patients undergoing hormone replacement therapy, abuse of alcohol, overt cerebrovascular, kidney or liver diseases, malignancies, as well as those who refused to participate in the study.

2.2. Clinical Assessment and Anthropometry {#sec2.2}
------------------------------------------

Initially, patients underwent a full anamnesis and physical examination. For brachial blood pressure measurements, a validated oscillometric device was used (Microlife, Widnau, Switzerland), with the cuff properly adapted to arm circumference. Three consecutive measures were taken, separated by one-minute interval each. The last two measures were averaged in order to obtain the mean for SBP and DBP. Heart rate (HR) was obtained simultaneously, with the last two measures averaged. Mean arterial pressure (MAP) was calculated according to the formula: MAP = (SBP + 2DBP)*·*3^−1^. Pulse pressure (PP) was obtained by subtraction between SBP and DBP.

Body weight was assessed using a precision digital scale (Filizola, São Paulo, Brazil) to the nearest 0.1 kg, with the individuals in standing position, barefoot and wearing light clothes. Height was measured at the highest head point to the nearest 0.5 cm, with a stadiometer coupled to the scale and the head in anatomical position. Body mass index (BMI) was defined as the ratio between the body weight and the square of the height, expressed in kg*·*m^−2^.

Waist circumference (WC, to the nearest 0.5 cm) was measured using a heavy-duty inelastic fiberglass tape (Cardiomed, Curitiba, Brazil) placed horizontally and tension free immediately over the skin at the midpoint between the last rib and the iliac crest, with measurements taken at the end of expiration. Neck circumference (NC) was assessed with the head in anatomical position, and the fiberglass tape placed right above the superior margin of the laryngeal prominence, parallel to the horizontal plane. Hip circumference (cm) was measured taking as reference the largest circumference on the hip anatomy, and waist-to-hip ratio (WHR) was then calculated. All anthropometric measurements were performed in the morning by an only physician previously trained.

2.3. Noninvasive Assessment of the Arterial Function {#sec2.3}
----------------------------------------------------

For noninvasively assessing the arterial function, the method of radial artery applanation tonometry was used, as described elsewhere \[[@B24]\]. All results were expressed as the average of the three measures captured by the sensor. The procedures were performed by a previously trained investigator broadly familiarized with the method.

2.4. Blood Samples Collection and General Biochemical Profile {#sec2.4}
-------------------------------------------------------------

For the biochemical analysis, patients underwent peripheral venous blood collection from an antecubital vein after a 12-hour overnight fasting. Immediately after, samples destined to the determination of general biochemical profile were processed according to standard laboratory techniques. Analytes for assessing the redox state were rapidly put in ice bath (4°C), being centrifuged at 1600 g for 10 minutes (Fanem, São Paulo, Brazil) to separate plasma from blood cellular elements. Next, plasma and erythrocyte samples were aliquoted and stored at −80°C until analysis.

2.5. Nonesterified Fatty Acids (NEFA) in Plasma {#sec2.5}
-----------------------------------------------

The NEFA quantification in plasma samples was assayed using a commercial kit (Wako Chemicals GmbH, Neuss, Germany), according to the manufacturer\'s protocol, with adaptations for microplate (Thermo Fisher Scientific, Vantaa, Finland). The results were expressed in mmol*·*L^−1^.

2.6. Fasting Insulin in Plasma {#sec2.6}
------------------------------

For quantitative insulin detection in plasma, a commercial ELISA kit was used (Millipore, Missouri, USA), following the manufacturer\'s instructions. A standard curve was used to determine insulin concentrations, with the results expressed in mU*·*L^−1^.

2.7. Assessment of Insulin Resistance {#sec2.7}
-------------------------------------

The degree of insulin resistance was estimated using the mathematical model HOMA-IR (Homeostasis Model Assessment − Insulin Resistance) index and calculated as follows: HOMA-IR = \[fasting insulin (*μ*U*·*L^−1^) × fasting glucose (mmol*·*L^−1^)\]/22.5  \[[@B25]\]. Values were expressed in *μ*U*·*L^−1^/mmol*·*L^−1^. High HOMA-IR values indicate a state of insulin resistance, while low HOMA-IR values are associated with better insulin sensitivity.

2.8. Estimation of the Glomerular Filtration Rate {#sec2.8}
-------------------------------------------------

Estimated glomerular filtration rate (eGFR) was calculated using the simplified MDRD (Modification of Diet in Renal Disease) formula, as follows: 186 × plasma creatinine^−1.154^  × age^−0.203^  × 1.212. For women, results were further multiplied by the constant 0.742 \[[@B26]\].

2.9. Lipid Peroxidation in Plasma {#sec2.9}
---------------------------------

The lipid peroxidation in plasma was quantified based on the protocol described by Ohkawa et al. \[[@B27]\], with slight adaptations, for determining the Thiobarbituric Acid Reactive Substances (TBARS), among which malondialdehyde (MDA) figures as the most representative one. Absorbance was read in a microplate reader (Thermo Fisher Scientific, Vantaa, Finland), at wavelengths of 532 nm and 600 nm. The dosages were performed in duplicate and TBARS values were normalized by total protein concentration in plasma \[[@B28]\], and expressed as *μ*M*·*\[Protein\] mg*·*mL^−1^.

2.10. Erythrocyte Lysates and Measurement of Hemoglobin Concentrations {#sec2.10}
----------------------------------------------------------------------

After thawing in ice bath (4°C), 250 *μ*L of erythrocyte samples were taken for hemolysis, being aliquoted and stored at −80°C, until the redox analyses were performed. Hemoglobin (Hb) concentrations in erythrocyte lysates were measured using a commercial kit (Labtest, Belo Horizonte, Brazil), according to the manufacturer\'s protocol.

2.11. Total Superoxide Dismutase (SOD) Activity in Erythrocytes and in Plasma {#sec2.11}
-----------------------------------------------------------------------------

Superoxide dismutase (SOD) activity was determined in erythrocyte lysates and in plasma, being read in microplate (Nunc, Roskilde, Denmark), using a commercial kit (Fluka, Sigma-Aldrich, St. Louis, USA), according to the manufacturer\'s protocol, at a wavelength of 450 nm (Thermo Fisher Scientific, Vantaa, Finland). Values were normalized by Hb concentrations and expressed in IU*·*mg Hb^−1^ in erythrocytes and by the total protein concentration \[[@B28]\] in plasma, with results expressed in IU*·*mg Protein^−1^.

2.12. Catalase Activity in Erythrocytes and in Plasma {#sec2.12}
-----------------------------------------------------

Catalase activity was measured in erythrocyte samples and in plasma in microplates (Nunc, Roskilde, Denmark), according to the protocol described by Xu et al. \[[@B29]\] and expressed in IU*·*mg Hb^−1^ in erythrocytes. For catalase activity in plasma, samples were directly plated in the wells, without dilution, before the reagent addition. Values were normalized by total protein concentration \[[@B28]\] and the enzyme activity, expressed as IU*·*mg Protein^−1^.

2.13. Hydrogen Peroxide (H~2~O~2~) Concentrations in Plasma {#sec2.13}
-----------------------------------------------------------

The quantification of plasma H~2~O~2~ levels was performed by fluorescence (Tecan 200 Infinite, Männedorf, Switzerland), with a commercial kit (Ultra Amplex Red Hydrogen Peroxide/Peroxidase Assay kit, Invitrogen, Paisley, UK), according to the manufacturer\'s instructions. In the presence of peroxidase (horseredish peroxidase, HRP), the Amplex Red reagent stoichiometrically reacts with H~2~O~2~ to form a red-fluorescent oxidation product, resorufin. A standard curve of H~2~O~2~ was prepared, with concentrations ranging from 0 to 10 *μ*M. Next, 50 *μ*L from the curve points or from the samples were plated in duplicate, with the addition of 50 *μ*L of the reagent/HRP solution to start the reaction. Finally, the black microplates (Nunclon Surface, Thermo Fisher Scientific, Vantaa, Finland) were incubated at room temperature for 120 minutes, protected from light and read at wavelengths of 530 and 590 nm, respectively, related to excitation and emission.

2.14. Myeloperoxidase (MPO) Activity in Plasma {#sec2.14}
----------------------------------------------

Similarly to the determination of H~2~O~2~ levels, MPO activity in plasma samples was performed using the Ultra Amplex Red Hydrogen Peroxide/Peroxidase Assay kit (Invitrogen, Paisley, UK), according to the manufacturer\'s instructions. A standard curve was prepared, with MPO concentrations ranging from 0.0312 to 1.0 UI*·*mL^−1^ (Sigma, St. Louis, USA). Then, 50 *μ*L of the curve points or from the samples were plated, with the addition of the Amplex Red/H~2~O~2~ working solution to start the reaction. Next, samples were incubated at room temperature for 150 minutes, protected from light. Finally, fluorescence was measured in a spectrofluorometer (Tecan 200 Infinite, Männedorf, Switzerland), using black microplates (Nunclon Surface, Thermo Fisher Scientific, Vantaa, Finland) at the wavelengths of 530 and 590 nm for excitation and emission, respectively.

2.15. Plasma Levels of Nitrite {#sec2.15}
------------------------------

The quantification of plasma nitrite concentrations was performed based on the protocol described by Misko et al. \[[@B30]\], with adaptations for microplates. This fluorimetric assay is based on the reaction between nitrite and the compound 2,3-diaminonaphthalene (DAN), originating 2,3-diaminonaphthotriazole. Initially, plasma samples were filtered using a 10 dKa molecular weight filter (Millipore, Missouri, USA). Then, using black 96-well microplates (Nunclon Surface, Thermo Fisher Scientific, Vantaa, Finland), to 50 *μ*L of each sample (in duplicate) were added 100 *μ*L of deionized water. Next, 10 *μ*L of DAN (0.05 mg*·*mL^−1^ in HCl 0.62 M) were added and mixed immediately, with DAN always protected from light. After incubation at 20°C for 10 minutes, the reaction was stopped by the addition of 5 *μ*L of NaOH (2.8 M). The compound formed was quantified in a spectrofluorometer (Tecan 200 Infinite, Männedorf, Switzerland), at 365 nm and 410 nm for excitation and emission, respectively. Nitrite concentrations were calculated based on a standard curve of nitrite.

2.16. Arginase Activity in Erythrocytes and in Plasma {#sec2.16}
-----------------------------------------------------

Arginase activity was determined using a colorimetric method, as previously described \[[@B31]\], with adaptations for microassays. Briefly, erythrocyte lysates were dissolved in PBS 1 : 20 (v : v) and homogenized under cooling. Next, 50 *μ*L from the solution were incubated with 75 *μ*L of a Tris-HCl (50 mmol*·*L^−1^ plus 10 mmol MnCl~2~; pH 7.5) solution supplemented with manganese chloride (10 mmol*·*L^−1^) at 60°C in an incubator during 10 minutes. After this, the reaction was initiated by the addition of 50 *μ*L of the substrate L-arginine (100 mmol*·*L^−1^) and processed at 37°C for 1 hour. At the end of this step, 400 *μ*L of an acid solution were added in order to stop the reaction. The reagent *α*-isonitroso-propiophenone (25 *μ*L; 9% in EtOH) was then added to the mixture, following another reaction for 45 minutes at 100°C. Finally, samples were incubated in the dark at room temperature for 10 minutes before reading. Absorbance was measured at 540 nm in a microplate reader (Thermo Fisher Scientific, Vantaa, Finland). Data were normalized according to hemoglobin concentrations, and enzyme activity was expressed in mmol/min/mL*·*mg Hb^−1^. For assessing the arginase activity in plasma, samples were not diluted but directly plated in the wells, with the other procedures similar to those applied during the determination of activity in erythrocytes. Data were normalized according to the total protein concentrations \[[@B28]\], and enzyme activity was expressed in mmol/min/mL*·*mg Protein^−1^.

2.17. Statistics {#sec2.17}
----------------

Data were analyzed using GraphPad Prism, version 5.00 (San Diego, CA, USA), and normality was tested applying the Shapiro-Wilk test. For continuous variables with normal distribution, the Student\'s *t*-test was used. For variables not presenting Gaussian distribution, the nonparametric Mann-Whitney*U* test was applied. Continuous variables are presented as mean ± standard deviation (SD) and categorical variables, in percentage. Linear regression analysis was also performed and results were considered significant if *P* \< 0.05.

3. Results {#sec3}
==========

3.1. Sample Characterization {#sec3.1}
----------------------------

The sample characterization evidenced the predominance of female patients in both groups ([Table 1](#tab1){ref-type="table"}). No significant differences were observed for age and height. As expected, for the MetS individuals, weight, BMI, WC, WHR, and NC were increased compared to the controls ([Table 1](#tab1){ref-type="table"}). Regarding drug therapy, 18 (75%) among all MetS patients were under regular use of medications for treating hypertension, dysglycemia/type 2 diabetes mellitus, or dyslipidemia ([Table 2](#tab2){ref-type="table"}). The participants in the control group were not under use of any pharmacological treatment.

3.2. A Hypertensive Pattern and a Marked Imbalance in Glucose Profile Were Found in MetS Patients, despite the Pharmacological Treatment {#sec3.2}
----------------------------------------------------------------------------------------------------------------------------------------

For the cardiovascular parameters, SBP, DBP, PP, and MAP were significantly higher in MetS patients than observed in the controls ([Table 1](#tab1){ref-type="table"}). For HR, however, no difference was identified between groups ([Table 1](#tab1){ref-type="table"}). Results concerning the glucose profile evidenced both higher fasting glucose and HbA1~C~ levels in MetS patients compared to the controls ([Table 1](#tab1){ref-type="table"}). Fasting insulinemia levels and the degree of insulin resistance were also increased in MetS patients ([Table 1](#tab1){ref-type="table"}).

3.3. Significant Dyslipidemia Accompanied the Dysglycemia in MetS Patients {#sec3.3}
--------------------------------------------------------------------------

MetS patients presented significant dyslipidemia, with higher levels for total cholesterol, triglycerides, and VLDL cholesterol compared to the controls ([Table 1](#tab1){ref-type="table"}). Furthermore, MetS individuals presented higher values for triglycerides/HDL cholesterol and total cholesterol/HDL cholesterol ratios, without significant differences for plasma concentrations of HDL cholesterol, LDL cholesterol, and NEFA ([Table 1](#tab1){ref-type="table"}).

3.4. MetS Patients Displayed Diminishment in Renal Function {#sec3.4}
-----------------------------------------------------------

When considering the parameters for renal assessment between groups, no significant difference for urea concentration in plasma was observed. Nevertheless, MetS patients showed decreased renal function compared to the controls, as observed by increased creatinine levels and lower eGFR ([Table 1](#tab1){ref-type="table"}).

3.5. MetS Patients Presented Elevated Uricemia and Liver Enzymes, without Changes in Neutrophil Count and in High-Sensitivity C-Reactive Protein Levels {#sec3.5}
-------------------------------------------------------------------------------------------------------------------------------------------------------

MetS individuals showed higher uric acid and AST and ALT concentrations in plasma, compared to the controls. Also, a reduction in the AST/ALT ratio was observed in the MetS group. However, for the hs-CRP levels, white blood cell count, and neutrophils, no differences between groups were observed ([Table 1](#tab1){ref-type="table"}).

3.6. The Lack of Difference between Groups for Arterial Stiffness and Nitrite Concentrations in Plasma Was Accompanied by Similar Arginase Activity {#sec3.6}
---------------------------------------------------------------------------------------------------------------------------------------------------

Results for the arterial stiffness assessment did not show significant difference between groups for the AI ([Figure 2(a)](#fig2){ref-type="fig"}). The lack of difference between groups was also observed when quantifying the nitrite levels in plasma ([Figure 2(b)](#fig2){ref-type="fig"}). For the arginase activity, no differences were observed between groups, neither in erythrocytes ([Figure 2(c)](#fig2){ref-type="fig"}), nor in plasma ([Figure 2(d)](#fig2){ref-type="fig"}).

3.7. Increased Erythrocyte SOD Activity Was Not Accompanied by Changes in Catalase Activities {#sec3.7}
---------------------------------------------------------------------------------------------

For total SOD activity in plasma, no significant difference was observed between groups ([Figure 3(a)](#fig3){ref-type="fig"}). For total SOD in erythrocytes, however, a significantly higher activity was found in MetS individuals ([Figure 3(b)](#fig3){ref-type="fig"}). Nevertheless, for the catalase activities, no significant differences between groups were identified (Figures [3(c)](#fig3){ref-type="fig"} and [3(d)](#fig3){ref-type="fig"}).

3.8. Augmented H~2~O~2~ Concentrations and MPO Activity May Contribute to Increased Lipid Peroxidation in Plasma {#sec3.8}
----------------------------------------------------------------------------------------------------------------

The analysis of H~2~O~2~ in plasma evidenced higher concentrations in patients with MetS compared to the controls ([Figure 4(a)](#fig4){ref-type="fig"}). In the same direction of the observation for H~2~O~2~ concentrations, MPO activity in plasma was found to be increased in MetS individuals ([Figure 4(b)](#fig4){ref-type="fig"}). The assessment of lipid peroxidation in plasma showed a greater state of systemic redox imbalance in MetS patients, as observed by the increased MDA concentrations in such group compared to the controls ([Figure 4(c)](#fig4){ref-type="fig"}). Linear regression analyses revealed positive and significant correlations between two MetS components (WC and fasting glucose) and MPO (Figures [5(f)](#fig5){ref-type="fig"} and [5(g)](#fig5){ref-type="fig"}, resp.) and also between fasting insulin and MPO ([Figure 5(h)](#fig5){ref-type="fig"}). For the other MetS components and LDL-c, no significant correlations were observed with MPO (Figures [5(a)](#fig5){ref-type="fig"}--[5(e)](#fig5){ref-type="fig"}). For the oxidative stress markers MDA, MPO, and H~2~O~2~, significant correlations were found between MDA and MPO and also between MPO and H~2~O~2~ but not between MDA and H~2~O~2~ ([Figure 6](#fig6){ref-type="fig"}).

4. Discussion {#sec4}
=============

The main findings of the present work point to the possible action of MPO on its cosubstrate, H~2~O~2~, amplifying the systemic lipoperoxidation, being unlikely the direct participation of such radical in this process, in the considered sample.

When assessing the oxidative status, a significant redox imbalance in the MetS group was observed compared to the controls, as identified by increased lipid peroxidation in the former. In this regard, a large body of evidence points to obesity as a critical determinant of systemic oxidative stress in humans \[[@B4], [@B32]\]. Thus, it is plausible to consider obesity, particularly that observed by increased WC, as a contributor for the augmented lipoperoxidation levels in MetS patients in this study. Indeed, we found a significant positive correlation between WC and MPO activity ([Figure 5(f)](#fig5){ref-type="fig"}). In line with these observations, Fujita et al. \[[@B33]\], in a case-control study, found increased levels of urinary 8-epi-prostaglandin F~2~ (a marker of systemic oxidative stress) in MetS carriers. Furthermore, such oxidative marker was shown to be strongly correlated with visceral obesity \[[@B33]\].

A significant dysglycemia, with increased insulin resistance, was another prominent feature of MetS patients in the present study. In this regard, our group showed that the increase in lipid peroxidation was positively correlated with fasting glucose and HbA1~C~ in diabetic patients \[[@B34]\]. These statements, together with the significant positive correlations between fasting glucose/fasting insulin and MPO activity (Figures [5(g)](#fig5){ref-type="fig"} and [5(h)](#fig5){ref-type="fig"}) in the current study, reinforce the probable participation of dysglycemia in the maintenance of the environment of redox imbalance in patients with MetS.

Our findings for lipid peroxidation are in line with those of Demircan et al. \[[@B13]\] and Armutcu et al. \[[@B8]\], as both groups observed, in case-control studies, increased plasma MDA levels in MetS individuals. In opposition to these findings, a case-control study with MetS patients by Sánchez-Rodríguez et al. \[[@B6]\] failed to show statistically significant differences between groups for lipoperoxidation. The apparent discrepancy between the aforementioned studies highlights the complexity with which the MetS presents itself in the clinical setting, so that it seems reasonable to consider other possible contributors for the state of lipid peroxidation identified, such as the accuracy of the methodologies used for estimating the degree of oxidative stress, age, the presence of comorbidities, and dietary habits \[[@B35]\]. We also found higher erythrocyte SOD activity in MetS patients. Indeed, SOD represents a first-line endogenous antioxidant defense, converting ^•^O~2~ ^−^ to O~2~ and H~2~O~2~ \[[@B36], [@B37]\]. Olusi, while studying the erythrocyte Cu-ZnSOD activity in obese individuals, observed reduced enzyme activity in these individuals, compared to counterparts without obesity. Viroonudomphol et al. \[[@B38]\], in turn, highlighted that SOD, by an adaptive response, may present augmented activity in states of increased lipoperoxidation, as a compensatory means to mitigate redox imbalance. Considering these observations, it is likely that the increased erythrocyte SOD activity found in the current study occurred as a compensatory response for opposing the increased lipid peroxidation.

Following the action of SOD on ^•^O~2~ ^−^, H~2~O~2~ may be converted to H~2~O and O~2~ under the actions of catalase or glutathione peroxidase (GPx) \[[@B10], [@B36]\]. Hence, in the present study, increased SOD activity was accompanied by augmented levels of H~2~O~2~, a substrate for catalase. However, no significant changes in catalase activities were observed. In view of the fact that GPx represents an antioxidant enzyme not assessed in our sample, it is not possible to exclude its participation in degrading H~2~O~2~.

MetS patients in the present study exhibited higher plasma MPO activity, compared to controls. This enzyme is already described as an important cardiovascular risk factor, capable of potentiating the oxidative effects of its cosubstrate, H~2~O~2~ \[[@B20]\].

In order to study the possible contribution of MPO activity and H~2~O~2~ concentrations in the determination of lipid peroxidation, linear regression analysis was performed, with the observation of a positive correlation between MPO activity and MDA plasma levels but not between H~2~O~2~ concentrations and MDA plasma levels ([Figure 6](#fig6){ref-type="fig"}). These data suggest the direct participation of MPO in increasing lipid peroxidation, with this fact not holding true for H~2~O~2~. Interestingly, the occurrence of a significant positive correlation between MPO activity and H~2~O~2~ ([Figure 6](#fig6){ref-type="fig"}) finally suggests that one of the pathways responsible for inducing lipid peroxidation seems to be strongly dependent on the action of MPO on its cosubstrate, H~2~O~2~, being unlikely the direct participation of such radical in this process. Considering the potential consumption of H~2~O~2~ by MPO, one could expect to observe an inverse correlation between such variables, as the increased MPO activity could respond for reduced H~2~O~2~ levels, but our data point to a direct correlation instead. This finding may be due to the fact that the augmentation in MPO activity and the H~2~O~2~ consumption are not occurring in a proportional manner, with the cosubstrate production surpassing its diminishment by MPO. The activity of this enzyme, albeit elevated in MetS patients, was not increased enough to determine reduced H~2~O~2~ levels, the latter proportionally higher as a consequence of the overt environment of redox imbalance observed.

After activation, by a process of degranulation, neutrophils release MPO, becoming depleted of this enzyme \[[@B18], [@B39]\]. Thus, despite the fact that no difference was observed between groups for neutrophil count ([Table 1](#tab1){ref-type="table"}), it is reasonable to consider that elevated MPO activity in plasma samples of MetS patients may come from activated leukocytes. In addition, insulin resistance is responsible for augmenting the levels of proinflammatory mediators \[[@B40]\]. Furthermore, adipocytes, particularly in obese individuals, release inflammatory cytokines which compromise the insulin signaling \[[@B41]\]. Both of these factors (insulin resistance and central obesity) were found in MetS patients, but no differences were observed between groups for the marker of systemic inflammation hs-CRP. However, chronic inflammation is also associated with increased expression of MPO \[[@B14]\]. Literature highlights the association between proinflammatory mediators and the pathogenesis of the MetS, once dysregulation in inflammatory responses in the muscle and liver may be observed in the course of that syndrome \[[@B42]\]. Thus, the lack of difference for hs-CRP between groups and the significant increase in plasma MPO activity in the case group point to the potential use of such enzyme as an adjuvant marker for assessing the inflammatory state of patients with MetS.

Currently, it is already recognized that arterial stiffness is independently associated with the occurrence of cardiovascular events \[[@B43], [@B44]\]. Among the available parameters for noninvasively assessing the degree of arterial stiffness, the AI presents a strong correlation with the gold-standard (the Pulse Wave Velocity, PWV) for studying aortic stiffness \[[@B44]\], being an important marker of arterial stiffness \[[@B24]\].

Several studies have demonstrated the increased arterial stiffness in individuals with MetS \[[@B7], [@B45]\]. The AI and the PWV, albeit described as markers of vascular stiffness \[[@B44], [@B46]\], are not always altered in the same direction. Kovaite et al. \[[@B47]\] did not find significant difference for the AI obtained from the radial artery between patients with and without MetS. Nevertheless, the authors observed an association between MetS and the increase in PWV \[[@B47]\]. These data, together with those found in the present report for arterial stiffness, highlight the importance of considering the methodological approach used for determining the existence of significant differences between groups, without overlooking other possible interfering factors. In the current study, nine patients (37.49%) in the MetS group ([Table 2](#tab2){ref-type="table"}) were taking angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor antagonists, a fact that may have, at some degree, contributed to reduce the effects of the renin-angiotensin system in the vascular wall. In addition, statins may reverse abnormalities related to the arterial stiffness \[[@B43], [@B46]\]. Also, metformin is associated with reduction in macrovascular events in patients with diabetes \[[@B48]\]. Thus, the potential effects of such drugs must be considered when assessing the vascular stiffness in patients under their use.

More interestingly, the lack of difference between groups for the AI, a possible indirect means for assessing the endothelial function \[[@B49]\], was accompanied by similar concentrations of nitrite in plasma (also a marker of endothelial function) \[[@B12]\] in both groups.

The ^•^NO levels in individuals with MetS are rather conflicting in the literature. Simão et al., in a case-control study, identified lower concentrations of nitrite/nitrate in the MetS group, reflecting lower concentrations of ^•^NO \[[@B50]\]. In opposition to these observations, Ueyama et al. \[[@B51]\] showed that the concentrations of nitrite/nitrate increased when the number of the MetS diagnostic criteria was progressively augmented in humans. Such finding was defined as "unexpected," and the authors suggested a possible compensatory pathway for increasing ^•^NO synthesis \[[@B51]\]. Taken together, such discrepancies may be related to the particularities of each considered sample, including the time of progression of the morbid process, and the presence and duration of pharmacological treatment. In this regard, in the present report, different drugs with potential to positively interfere on the endothelial function had been regularly used by MetS patients, such as ACE inhibitors, angiotensin receptor antagonists \[[@B52]\], metformin, and statins \[[@B53]\].

For arginase activity, no significant differences were observed between groups. This enzyme, predominantly expressed in the liver, kidneys, and erythrocytes, converts L-arginine to urea and ornithine \[[@B54]\]. Under conditions of increased arginase activity, a reduction in ^•^NO production may be observed, as such enzyme competes with eNOS for the same substrate, L-arginine \[[@B55]\]. In situations of metabolic injury, changes in arginase activity are already described, as was the case with the augmented basal serum arginase activity in diabetic patients compared to controls \[[@B54]\]. The lack of difference for arginase activity between groups in the current report may point to the unrepresentative participation of plasma and erythrocyte arginase in the cardiometabolic dysregulation observed in the MetS group. It is not possible, however, to rule out the participation of this enzyme in other tissue microenvironments not assessed in the present study.

Finally, the exact mechanisms that determine redox imbalance in MetS in humans have yet to be better dissected, but our findings give insight into the comprehension of an enzymatic pathway possibly involved in this process. Thus, we do believe that this observation may shed some light on the possibility of pharmacological strategies in order to mitigate the cardiometabolic derangements found in the course of MetS.

Some limitations deserve to be mentioned in this study. Firstly, the relatively small sample size does not ensure that the lack of significant difference for some parameters assessed really occurs in the general population, so that further studies are required to consider this possibility. Secondly, as an observational, case-control study, it is not possible to establish a causal relationship between the variables studied.

5. Perspectives {#sec5}
===============

So far as we are aware, it is the first study pointing to the possible participation of MPO in amplifying the oxidative effects of H~2~O~2~ on systemic lipid peroxidation. Once lipoperoxidation was found to be dependent on the action of MPO, further studies are warranted to identify other possible contributing pathways in this process, but our data point to MPO/H~2~O~2~ as a potential therapeutic target in cardiometabolic diseases.
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![Study flow-chart. MetS: Metabolic Syndrome.](OMCL2014-898501.001){#fig1}

![(a) Augmentation Index (AI), (b) nitrite concentrations, and ((c) and (d)) arginase activities in patients with Metabolic Syndrome (MetS; *n* = 24) and controls (*n* = 18). Student\'s *t*-test for AI and nitrite concentrations. Mann-Whitney *U* test for arginase activities.](OMCL2014-898501.002){#fig2}

![((a) and (b)) Superoxide dismutase (SOD) and ((c) and (d)) catalase activities in patients with Metabolic Syndrome (MetS; *n* = 24) and controls (*n* = 18). Student\'s *t*-test for SOD and catalase in plasma. Mann-Whitney *U* test for SOD and catalase in erythrocytes. ^\*\*^ *P* \< 0.01.](OMCL2014-898501.003){#fig3}

![(a) Plasma hydrogen peroxide (H~2~O~2~) concentrations, (b) myeloperoxidase (MPO) activity, and (c) lipid peroxidation (MDA: malondialdehyde) in patients with Metabolic Syndrome (MetS; *n* = 24) and controls (*n* = 18). Student\'s *t*-test for H~2~O~2~ and MPO. Mann-Whitney *U* test for lipid peroxidation. ^\*\*^ *P* \< 0.01; ^\*\*\*^ *P* \< 0.0001.](OMCL2014-898501.004){#fig4}

![Linear regression analyses between myeloperoxidase (MPO) activity and (a) systolic blood pressure (SBP); (b) diastolic blood pressure; (c) HDL cholesterol (HDL-c) levels; (d) LDL cholesterol (LDL-c) levels; (e) triglycerides; (f) central obesity; (g) fasting glucose; and (h) fasting insulin. For LDL-c levels, *n* = 41 because in the MetS group one patient exhibited triglyceride levels greater than 400 mg*·*dL^−1^, thus impairing the determination of LDL-c levels. For the other parameters assessed, *n* = 42.](OMCL2014-898501.005){#fig5}

![Linear regression analysis for the main oxidative parameters significantly altered between groups (*n* = 42). MPO: myeloperoxidase. H~2~O~2~: hydrogen peroxide. MDA: malondialdehyde.](OMCL2014-898501.006){#fig6}

###### 

General, anthropometric, cardiovascular, and biochemical characteristics of participants included in the study.

  -----------------------------------------------------------------------------------------------------------------------------
                                                          Control group\   MetS group\            *P* values                
                                                          (*n* = 18)       (*n* = 24)^a^                                    
  ------------------------------------------------------- ---------------- ---------------------- ------------ ------------ ---
  General and anthropometric characteristics                                                                                

  Gender                                                  ♂ (*n*/%)\       ♀ (*n*/%)\             ♂ (*n*/%)\   ♀ (*n*/%)\    
                                                          5/27.77          13/72.23               6/25         18/75        

  Smoking                                                 1/5.56           2/8.33                                           

  Age (years)^b^                                          45.50 ± 7.45     50.17 ± 8.27           NS                        

  Weight (kg)^c^                                          68.63 ± 11.04    79.86 ± 17.83∗         0.02                      

  Height (m)^c^                                           1.60 ± 0.10      1.58 ± 0.10            NS                        

  BMI (kg*·*m^−2^)^c^                                     26.69 ± 3.27     32.09 ± 7.10∗∗         0.0073                    

  WC (cm)^b^                                              87.89 ± 7.65     103.30 ± 13.96∗∗∗      0.0001                    

  WHR^b^                                                  0.83 ± 0.06      0.90 ± 0.09∗∗          0.0042                    

  NC (cm)^c^                                              34.92 ± 3.24     37.46 ± 5.99∗          0.03                      

                                                                                                                            

  Cardiovascular parameters                                                                                                 

  SBP (mmHg)^c^                                           116.60 ± 9.18    134.00 ± 15.36∗∗∗      0.0007                    

  DBP (mmHg)^b^                                           75.44 ± 5.92     81.75 ± 8.53∗∗         0.0078                    

  MAP (mmHg)^b^                                           89.16 ± 5.94     99.16 ± 9.41∗∗∗        0.0003                    

  PP (mmHg)^b^                                            41.14 ± 8.51     52.23 ± 12.24∗∗        0.0021                    

  HR (bpm)^b^                                             72.58 ± 13.47    70.94 ± 12.68          NS                        

                                                                                                                            

  Glycemic profile, insulinemia, and insulin resistance                                                                     

  Fasting glucose (mg*·*dL^−1^)^c^                        80.11 ± 6.67     127.80 ± 64.10∗∗∗      \<0.0001                  

  HbA1c (%)^c^                                            4.99 ± 0.26      6.50 ± 1.66∗∗∗         \<0.0001                  

  Insulinemia (mU*·*L^−1^)^c^                             8.95 ± 4.44      13.60 ± 6.21∗∗∗        \<0.0001                  

  HOMA-IR (*µ*U*·*mL^−1^)^c^                              1.80 ± 1.06      4.58 ± 3.95∗∗∗         \<0.0001                  

                                                                                                                            

  Lipid profile                                                                                                             

  Total cholesterol (mg*·*dL^−1^)^b^                      182.70 ± 29.83   225.60 ± 53.86^\*\*^   0.0041                    

  Triglycerides (mg*·*dL^−1^)^c^                          81.39 ± 22.91    180.90 ± 110.30∗∗∗     \<0.0001                  

  HDL (mg*·*dL^−1^)^c^                                    49.17 ± 5.76     48.63 ± 15.08          NS                        

  LDL (mg*·*dL^−1^)^b^                                    117.80 ± 28.78   139.70 ± 41.54         NS                        

  VLDL (mg*·*dL^−1^)^c^                                   15.57 ± 4.47     36.18 ± 22.06∗∗∗       \<0.0001                  

  TG/HDL ratio^c^                                         1.69 ± 0.56      4.01 ± 2.48∗∗∗         \<0.0001                  

  TC/HDL ratio^c^                                         3.76 ± 0.72      4.81 ± 1.07∗∗          0.0008                    

  NEFA (mmol*·*L^−1^)^b^                                  0.32 ± 0.10      0.36 ± 0.09            NS                        

                                                                                                                            

  Renal function parameters                                                                                                 

  Urea (mg*·*dL^−1^)^b^                                   25.17 ± 7.13     29.58 ± 7.50           NS                        

  Creatinine (mg*·*dL^−1^)^b^                             0.77 ± 0.15      0.90 ± 0.18∗           0.0207                    

  eGFR (mL/min/1.73 m^2^)^b^                              119.00 ± 27.12   95.23 ± 21.92∗∗        0.0031                    

                                                                                                                            

  Others parameters                                                                                                         

  WBC count (cells/mm^3^)^b,d^                            6617 ± 1659      6400 ± 1744            NS                        

  Neutrophils (cells/mm^3^)^b,d^                          3934 ± 1553      3585 ± 1132            NS                        

  Neutrophils (%)^c,d^                                    57.72 ± 11.09    55.71 ± 6.79           NS                        

  Uric acid (mg*·*dL^−1^)^b^                              3.31 ± 0.80      4.11 ± 1.14∗           0.0150                    

  AST (U*·*mL^−1^)^c^                                     21.50 ± 8.05     32.63 ± 20.83∗         0.0127                    

  ALT (U*·*mL^−1^)^c^                                     22.33 ± 9.77     46.88 ± 35.96∗∗∗       0.0006                    

  AST/ALT ratio^b^                                        1.01 ± 0.29      0.78 ± 0.23∗∗          0.0063                    

  hs-CRP (mg*·*L^−1^)^c^                                  2.77 ± 2.30      3.59 ± 3.94            NS                        
  -----------------------------------------------------------------------------------------------------------------------------

Values are expressed as mean ± standard deviation. ^a^For LDL-c levels in the MetS group, *n* = 23 because one patient exhibited triglyceride levels greater than 400 mg*·*dL^−1^, thus impairing the determination of LDL-c levels. For the other parameters assessed in the MetS group, *n* = 24. ^b^Student\'s *t* Test. ^c^Mann-Whitney *U* Test. ^d^Values obtained from peripheral venous blood samples. NS: nonsignificant. ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; HbA1c: glycated hemoglobin; HDL: high density lipoprotein cholesterol; HOMA-IR: homeostasis model assessment-insulin resistance; HR: heart rate; hs-CRP: high-sensitivity C-reactive protein; LDL: low density lipoprotein; MAP: mean arterial pressure; NC: neck circumference; NEFA: non-esterified fatty acids; PP: pulse pressure; SBP: systolic blood pressure; TC: total cholesterol; TG: triglycerides; VLDL: very low density lipoprotein; WBC: white blood cell; WC: waist circumference; WHR: waist-to-hip ratio. ^\*^ *P* \< 0.05; ^\*\*^ *P* \< 0.01; ^\*\*\*^ *P* \< 0.0001.

###### 

Medications used by patients presenting with MetS.

  Medications                             (patients under use/total)   \%
  --------------------------------------- ---------------------------- -------
  *β*-blockers                            5/24                         20.83
  Diuretics                               6/24                         25.00
  ACE inhibitors                          5/24                         20.83
  Angiotensin AT~1~ receptor antagonist   4/24                         16.66
  Calcium channel blockers                4/24                         16.66
  Aldosterone antagonist                  1/24                         4.16
  Metformin                               6/24                         25.00
  Glibenclamide                           4/24                         16.66
  Statins                                 3/24                         12.50
  NPH insulin                             1/24                         4.16

Values do not sum 100% because some patients were under combined pharmacological treatment. ACE: angiotensin converting enzyme.

[^1]: Academic Editor: Qingping Feng
